Regenxbio Inc (RGNX)

11.14 +0.46 (+4.26%) USD  |  NASDAQ  |  Nov 14, 16:00
11.58 +0.44 (+4.00%) After-Hours: 18:17
More

Regenxbio Research and Development Expense (Quarterly): 54.43M for Sept. 30, 2024

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2014. Upgrade now.
Date Value
September 30, 2024 54.43M
June 30, 2024 48.87M
March 31, 2024 54.84M
December 31, 2023 55.68M
September 30, 2023 58.18M
June 30, 2023 59.89M
March 31, 2023 58.52M
December 31, 2022 62.50M
September 30, 2022 63.31M
June 30, 2022 61.01M
March 31, 2022 55.63M
December 31, 2021 47.98M
September 30, 2021 47.86M
June 30, 2021 45.88M
March 31, 2021 39.72M
December 31, 2020 47.18M
September 30, 2020 43.97M
June 30, 2020 38.11M
March 31, 2020 37.04M
December 31, 2019 33.81M
September 30, 2019 35.69M
Date Value
June 30, 2019 29.48M
March 31, 2019 25.20M
December 31, 2018 24.33M
September 30, 2018 18.51M
June 30, 2018 21.49M
March 31, 2018 19.55M
December 31, 2017 14.17M
September 30, 2017 12.52M
June 30, 2017 13.92M
March 31, 2017 16.62M
December 31, 2016 16.06M
September 30, 2016 12.56M
June 30, 2016 10.68M
March 31, 2016 6.183M
December 31, 2015 4.808M
September 30, 2015 5.664M
June 30, 2015 4.012M
March 31, 2015 2.791M
December 31, 2014 2.092M
September 30, 2014 1.085M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

33.81M
Minimum
Dec 2019
63.31M
Maximum
Sep 2022
50.72M
Average
51.65M
Median

Research and Development Expense (Quarterly) Benchmarks

Catalyst Pharmaceuticals Inc 3.284M
EyePoint Pharmaceuticals Inc 29.82M
Cassava Sciences Inc 17.68M
Vertex Pharmaceuticals Inc 875.90M
Sarepta Therapeutics Inc 224.48M